Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug–drug interactions

Sunitinib, a CYP3A4 substrate, is standard of care treatment in metastatic renal cell carcinoma (mRCC) and is administered orally as a single dose of 50 mg, in a 4 weeks on/2 weeks off regimen. Frequently, dose reduction is necessary because of toxicity, as is the association of comedication to treat side effects. In addition, existing comorbidities in these patients necessitate the intake of various classes of chronic medication. Only limited data are available on the risk of drug–drug interactions (DDI). The objective of our paper was to evaluate prescribed dose, comedication, risk of drug–drug interactions and outcome among patients with mRCC treated with sunitinib.

[1]  R. Mathijssen,et al.  Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs , 2013, British Journal of Cancer.

[2]  R. Motzer,et al.  A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Rottey,et al.  NEPHROTOXICITY OF ANTICANCER DRUGS – AN UNDERESTIMATED PROBLEM? , 2011, Acta clinica Belgica.

[4]  J. Hugtenburg,et al.  Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  P. Albers,et al.  Sunitinib for the treatment of metastatic renal cell carcinoma. , 2011, Cancer treatment reviews.

[6]  R. Figlin,et al.  Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib , 2011, Journal of the National Cancer Institute.

[7]  J. Burke,et al.  Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. de Lemos,et al.  Quality and usability of common drug information databases. , 2010, The Canadian journal of hospital pharmacy.

[9]  B. Decallonne,et al.  Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? , 2010, Thyroid : official journal of the American Thyroid Association.

[10]  V. Kataja,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Suneet Shukla,et al.  Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2 , 2009, Drug Metabolism and Disposition.

[13]  P. Carmeliet,et al.  The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation , 2008, British Journal of Cancer.

[14]  R. Figlin,et al.  Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) , 2008 .

[15]  C. Charbonneau,et al.  Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. , 2008, Cancer treatment reviews.

[16]  J. Ferlay,et al.  The changing pattern of kidney cancer incidence and mortality in Europe , 2008, BJU international.

[17]  John M. Darrington,et al.  A new methodology for assessment of the performance of heartbeat classification systems , 2008, BMC Medical Informatics Decis. Mak..

[18]  M. Gordon,et al.  Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .

[19]  P. Davis,et al.  Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. , 2007, Journal of the National Cancer Institute.

[20]  Hyla H. Polen,et al.  Clinical decision support tools: analysis of online drug information databases , 2007, BMC Medical Informatics Decis. Mak..

[21]  W. Kaelin.  The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma , 2007, Clinical Cancer Research.

[22]  R Y Ball,et al.  Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs , 2005 .